Comparison of the effect of dietary approaches to stop hypertension (DASH) diet to improve non-alcoholic fatty liver disease

Not Applicable

Conditions: on-alcoholic fatty liver disease.
Fatty (change of) liver, not elsewhere classified
K76.0

Registration Number: IRCT20121029011307N2

Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 120

Inclusion Criteria

Having a non alcoholic fatty liver disease (NAFLD) to diagnose a doctor (using Ultra Ultrasound)
willing to participate in the study

Exclusion Criteria

Patients with cardiovascular disease, liver disease (cirrhosis, alcoholic liver disease, viral hepatitis, autoimmune hepatitis, primary bile cirrhosis, bile obstruction, liver damage induced by hereditary hemochromatosis drugs, sclerosis, and a-antitrypsin deficiency), other dire diseases Such as cancer, kidney failure and... Celiac
Pregnancy, lactation
Taking medications that cause fatty liver (methotrexate, tamoxifen, Oalprowat, etc.)
Taking blood lipid-lowering drugs
Malnutrition
Having certain diets like vegetarian and raw veganism
Alcohol consumption

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fatty liver severity. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: Using Ultrasound.

Secondary Outcome Measures

Name	Time	Method
Isoprostane 8. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: Enzyme-linked immunosorbent kit.;Interleukin 6. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: Enzyme-linked immunosorbent kit.;C-Reactive Protein. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: Enzyme-linked immunosorbent kit.;Aspartate aminotransferase. Timepoint: At the beginning of the study (before intervention) and three months after the beginning of the intervention. Method of measurement: Calorimetry method.